Testing new drugs for cancers with FGFR gene changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific change in the FGFR2 or FGFR3 gene, confirmed by a lab test.
- You must have advanced cancer that has spread or cannot be removed with surgery.
- If you have gastric or esophageal cancer, you must have a type that is HER2-negative and have had little or no prior treatment.
- If you have lung cancer, you must have tried at least one standard treatment and you should not have certain other gene changes (like EGFR or ALK) unless you've had targeted therapy.
- You cannot have had prior treatment with a FGFR-targeted drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This trial tests a combination of two experimental drugs, ABSK043 and Glecirasib, for people with a specific type of advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination works better than standard treatments.
This trial tests two new targeted drugs (ABSK-011 and ABSK043) for people with advanced liver cancer whose tumors have high levels of the FGF19 protein and who have already tried at least one other treatment.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.